- Conditions
- Chronic Lymphocytic Leukemia, CLL/SLL
- Interventions
- Acalabrutinib
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2185–2208
of 2,816
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hematologic Malignancies, Acute Myeloid Leukemia, Lymphoid Leukemia, Chronic Myeloid Leukemia, Hodgkin's Disease, Non-Hodgkin's Lymphoma, Myelodysplastic Syndromes
- Interventions
- StemEx®
- Drug
- Lead sponsor
- Gamida Cell -Teva Joint Venture Ltd.
- Other
- Eligibility
- 12 Years to 55 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Orange, California • Aurora, Colorado + 10 more
- Conditions
- Lymphoma
- Interventions
- busulfan, cyclophosphamide, etoposide, allogeneic bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 15 Years to 60 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2004
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Leukemia, Lymphoma
- Interventions
- Forodesine Hydrochloride Sterile Solution, 5 mg/mL, Forodesine Hydrochloride Capsules (100 mg)
- Drug
- Lead sponsor
- BioCryst Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Shreveport, Louisiana • Valhalla, New York + 2 more
- Conditions
- Acute Leukemia, Hematologic and Lymphocytic Disorder, Myelodysplastic Syndrome, Primary Myelofibrosis, Secondary Myelofibrosis
- Interventions
- Fludarabine, Itacitinib Adipate, Melphalan, Quality-of-Life Assessment, Questionnaire Administration, Sirolimus, Tacrolimus
- Drug · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Leukemia
- Interventions
- anti-thymocyte globulin, cyclophosphamide, cytarabine, methylprednisolone, thiotepa, allogeneic bone marrow transplantation, in vitro-treated bone marrow transplantation, low-LET electron therapy, low-LET photon therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1993 – 2003
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
- Interventions
- Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Prophylactic Cranial Irradiation, Thioguanine, Vincristine Sulfate
- Drug · Other · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2021
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Long Beach, California • Los Angeles, California + 20 more
- Conditions
- Relapsed/Refractory Philadelphia Positive B-precursor ALL
- Interventions
- Blinatumomab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 8
- States / cities
- Duarte, California • La Jolla, California • Atlanta, Georgia + 5 more
- Conditions
- Leukemia, Myelodysplastic Syndromes
- Interventions
- anti-thymocyte globulin, peripheral blood lymphocyte therapy, fludarabine phosphate, methylprednisolone, thiotepa, allogeneic hematopoietic stem cell transplantation, in vitro-treated peripheral blood stem cell transplantation, total-body irradiation
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- Up to 50 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2018
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Gainesville, Florida • Boston, Massachusetts + 1 more
- Conditions
- Stem Cell Transplantation, Pediatric Cancer, Acute Lymphoblastic Leukemia
- Interventions
- Cognitive rehabilitation program
- Behavioral
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 6 Years to 21 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Executive Functioning, Pediatric ALL
- Interventions
- Zengar Electroencephalogram (EEG) Neurofeedback device
- Device
- Lead sponsor
- Northern Arizona University
- Other
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Prescott, Arizona
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- ABT-263, FCR, BR
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 6
- States / cities
- La Jolla, California • Stanford, California • Baltimore, Maryland + 3 more
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Leukemia in Remission, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, Aplastic Anemia, B-Cell Non-Hodgkin Lymphoma, CD40 Ligand Deficiency, Chronic Granulomatous Disease, Chronic Leukemia in Remission, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Congenital Amegakaryocytic Thrombocytopenia, Congenital Neutropenia, Congenital Pure Red Cell Aplasia, Glanzmann Thrombasthenia, Immunodeficiency Syndrome, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Paroxysmal Nocturnal Hemoglobinuria, Plasma Cell Myeloma, Polycythemia Vera, Recurrent Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome, Severe Aplastic Anemia, Shwachman-Diamond Syndrome, Sickle Cell Disease, T-Cell Non-Hodgkin Lymphoma, Thalassemia, Waldenstrom Macroglobulinemia, Wiskott-Aldrich Syndrome
- Interventions
- Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Peripheral Blood Stem Cell Transplantation, Total-Body Irradiation
- Drug · Other · Procedure + 1 more
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 1 Year to 75 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia
- Interventions
- Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Echocardiography Test, FDG-Positron Emission Tomography, Leucovorin, Levoleucovorin, Lumbar Puncture, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Methylprednisolone, Multigated Acquisition Scan, Prednisolone, Prednisone, Therapeutic Hydrocortisone, Thioguanine, Venetoclax, Vincristine
- Drug · Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 365 Days
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 116
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 100 more
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Leukemia
- Interventions
- silymarin
- Dietary Supplement
- Lead sponsor
- Herbert Irving Comprehensive Cancer Center
- Other
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2010
- U.S. locations
- 7
- States / cities
- Miami, Florida • Mineola, New York • New York, New York + 3 more
- Conditions
- Leukemia
- Interventions
- DNA analysis, fluorescence in situ hybridization, gene expression analysis, microarray analysis, mutation analysis, polymerase chain reaction, laboratory biomarker analysis
- Genetic · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Interventions
- PCV13 vaccine and any of the FDA-approved COVID-19 vaccine products (BNT162b2, mRNA-1273, or Ad26.COV2.S) based on local availability.
- Biological
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Leukemia, Lymphoma, Myeloma
- Interventions
- Busulfan, Gemcitabine, Melphalan, Hematopoietic Cell Transplantation, Rituximab for Patients with B-Cell Malignancies, Palifermin
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Leukemia, Lymphocytic, Acute, L1
- Interventions
- Not listed
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- 4 Years to 18 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Umbralisib
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Marginal Zone Lymphoma
- Interventions
- Acalabrutinib, Rituximab, Ifosfamide, Carboplatin, Etoposide
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- B-cell Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukemia, Adult, B-ALL
- Interventions
- Blinatumomab Injection
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- huCART19
- Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 3 Months to 29 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Accelerated Phase CML, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Chronic Lymphocytic Leukemia, Chronic Phase CML, BCR-ABL1 Positive, Cytomegalovirus Positive, Donor, Hematopoietic Cell Transplant Recipient, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Myelofibrosis, Hematopoietic and Lymphoid Cell Neoplasm
- Interventions
- Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
- Biological
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California